A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910